KromaTiD Announces Third U.S. Patent and New Proprietary Capabilities
Fort Collins, Colorado September 21, 2015: With the issuance of its third U.S. patent (#9,090,935 B2), KromaTiD is pleased to announce an expansion of its full genome screening platform to include a new set of unique methods for understanding the structure of novel disease causing mutations.
dGH assays are unique in their ability to detect the widest range of disease-causing genetic rearrangements, including chromosomal inversions and chromosomal translocations—mutations usually missed by other genomic tools, including today’s advanced sequencing technologies. Based on its proprietary chromatid-specific imaging platform, KromaTiD’s dGH™ is the only imaging technology capable of determining DNA sequence, location and orientation data in a single test. With these new capabilities, KromaTiD is now able to estimate the size of DNA rearrangements in the same assay.
“Our customers are developing precision medicines and interventions for diseases such as cancers and developmental disorders” says Chris Tompkins, KromaTiD’s President and COO. “With dGH’s new capability we can provide them with a deeper understanding of disease genetics during early screening and discovery studies, speeding results and making a meaningful impact on their programs.”
KromaTiD’s commercial offering includes kits & assays for detecting known DNA rearrangements and for discovering new disease-causing rearrangements, custom assays for tracking rearrangements to genes and for validating results from sequencing and arrays. KromaTiD also offers its customers affordable assay and sample processing services that deliver high quality data in a timely fashion.
To learn more about KromaTiD’s product and services offerings, visit www.kromatid.com in the US or www.tebu-bio.com in Europe.
KromaTiD, Inc. is a Colorado-based bioscience company dedicated to creating new products for genetic disease research, mutation detection and chromosome analysis. KromaTiD’s patented directional Genomic Hybridization (dGH™) chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations. KromaTiD develops and markets dGH technology under license from Colorado State University.